SCHEMBL6309934

SCHEMBL6309934

CCCCc1c(C)c(C#N)c2nc3ncccc3n2c1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.71
MAPT P10636 4/20 0.71
NPSR1 Q6W5P4 4/20 0.71
SMN1; SMN2 Q16637 4/20 0.71
RAB9A P51151 2/20 0.71
HPGD P15428 2/20 0.71
HTT P42858 2/20 0.71
HSP90AA1 P07900 1/20 0.58
LMNA P02545 3/20 0.56
NPC1 O15118 1/20 0.56
MDM2 Q00987 1/20 0.56
MEN1 O00255 5/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SLC2A1 P11166 1/20 0.48
KDM4E B2RXH2 7/20 0.45
ALDH1A1 P00352 7/20 0.45
GAA P10253 4/20 0.45
HK1 P19367 1/20 0.44
HKDC1 Q2TB90 1/20 0.44
APAF1 O14727 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6312080 0.83 NPSR1 (1.00) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6310807 0.81 KMT2A (0.72) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL14478838 0.80 KMT2A (0.93) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6310738 0.79 KMT2A (0.91) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6311557 0.79 KMT2A (0.91) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6313411 0.78 LMNA (0.47) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6311038 0.76 KMT2A (0.72) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6313600 0.76 KMT2A (0.72) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6310356 0.76 L3MBTL1 (0.46) KMT2AMAPTNPSR1SMN1; SMN2RAB9A
SCHEMBL6312317 0.74 MAPT (0.41) KMT2AMAPTNPSR1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 KMT2A 4210/4885MAPT 1694/4885NPSR1 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.